{"id":45372,"date":"2025-10-31T11:06:37","date_gmt":"2025-10-31T03:06:37","guid":{"rendered":"https:\/\/flcube.com\/?p=45372"},"modified":"2025-10-31T11:06:38","modified_gmt":"2025-10-31T03:06:38","slug":"novo-nordisk-launches-9-billion-unsolicited-bid-for-metsera-triggering-battle-with-pfizer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45372","title":{"rendered":"Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer"},"content":{"rendered":"\n<p><strong>Novo Nordisk A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) announced today an unsolicited offer of <strong>USD\u202f9\u202fbillion<\/strong> for <strong>Metsera, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/MTSR:NASDAQ\">NASDAQ: MTSR<\/a>), a U.S. obesity\u2011drug developer. The bid aims to outpace <strong>Pfizer<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>), which had previously agreed to acquire Metsera for <strong>USD\u202f7.5\u202fbillion<\/strong> in a definitive deal announced on September\u202f22.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bid-structure\"><strong>Bid Structure<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Offer<\/th><th>Up\u2011front Cash<\/th><th>Potential Milestone Pay\u2011out<\/th><th>Total Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Novo\u202fNordisk<\/strong><\/td><td>USD\u202f56.50 per share (\u2248\u202fUSD\u202f6.5\u202fbillion)<\/td><td>USD\u202f21.25 per share if clinical &amp; regulatory milestones are met<\/td><td>USD\u202f9\u202fbillion<\/td><\/tr><tr><td><strong>Pfizer<\/strong><\/td><td>USD\u202f47.50 per share (\u2248\u202fUSD\u202f4.9\u202fbillion)<\/td><td>USD\u202f22.50 per share upon milestone attainment<\/td><td>USD\u202f7.5\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-metsera-s-response\"><strong>Metsera\u2019s Response<\/strong><\/h2>\n\n\n\n<p>Metsera confirmed that it has notified Pfizer that Novo\u202fNordisk\u2019s proposal is a \u201csuperior company proposal.\u201d Under the terms of the existing agreement, Pfizer has a four\u2011day window to revise its offer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pfizer-s-counter-statement\"><strong>Pfizer\u2019s Counter\u2011Statement<\/strong><\/h2>\n\n\n\n<p>Pfizer called Novo\u202fNordisk\u2019s action \u201creckless and unprecedented,\u201d alleging that the bid \u201cattempts to suppress competition in violation of law\u201d and \u201ccircumvents antitrust regulations.\u201d Pfizer stated it will pursue all legal avenues to enforce its rights under the agreement.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-board-of-directors-rationale\"><strong>Board of Directors\u2019 Rationale<\/strong><\/h2>\n\n\n\n<p>Metsera\u2019s board had previously rejected Novo\u202fNordisk\u2019s proposal due to \u201ca variety of risks\u201d in its deal structure. The board selected Pfizer because it could \u201ccomplete an acquisition of 100\u202f% of Metsera\u2019s equity with the same level of certainty or on the same expected timeline.\u201d The Pfizer transaction is said to deliver \u201creal, certain and immediate value\u201d for shareholders and fast\u2011track Metsera\u2019s key drug candidate into the U.S. market.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S (NYSE: NVO) announced today an unsolicited offer of USD\u202f9\u202fbillion for Metsera, Inc&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":45373,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,20,4364,4365,148,860,863,309],"class_list":["post-45372","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-finance","tag-metsera","tag-nasdaq-mtsr","tag-novo-nordisk","tag-nyse-nvo","tag-nyse-pfe","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced today an unsolicited offer of USD\u202f9\u202fbillion for Metsera, Inc. (NASDAQ:\u202fMTSR), a U.S. obesity\u2011drug developer. The bid aims to outpace Pfizer (NYSE: PFE), which had previously agreed to acquire Metsera for USD\u202f7.5\u202fbillion in a definitive deal announced on September\u202f22.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45372\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced today an unsolicited offer of USD\u202f9\u202fbillion for Metsera, Inc. (NASDAQ:\u202fMTSR), a U.S. obesity\u2011drug developer. The bid aims to outpace Pfizer (NYSE: PFE), which had previously agreed to acquire Metsera for USD\u202f7.5\u202fbillion in a definitive deal announced on September\u202f22.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45372\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T03:06:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T03:06:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45372#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45372\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer\",\"datePublished\":\"2025-10-31T03:06:37+00:00\",\"dateModified\":\"2025-10-31T03:06:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45372\"},\"wordCount\":289,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45372#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3101.webp\",\"keywords\":[\"Biotech\",\"Finance\",\"Metsera\",\"NASDAQ: MTSR\",\"Novo Nordisk\",\"NYSE: NVO\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45372#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45372\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45372\",\"name\":\"Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45372#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45372#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3101.webp\",\"datePublished\":\"2025-10-31T03:06:37+00:00\",\"dateModified\":\"2025-10-31T03:06:38+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE: NVO) announced today an unsolicited offer of USD\u202f9\u202fbillion for Metsera, Inc. (NASDAQ:\u202fMTSR), a U.S. obesity\u2011drug developer. The bid aims to outpace Pfizer (NYSE: PFE), which had previously agreed to acquire Metsera for USD\u202f7.5\u202fbillion in a definitive deal announced on September\u202f22.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45372#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45372\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45372#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45372#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE: NVO) announced today an unsolicited offer of USD\u202f9\u202fbillion for Metsera, Inc. (NASDAQ:\u202fMTSR), a U.S. obesity\u2011drug developer. The bid aims to outpace Pfizer (NYSE: PFE), which had previously agreed to acquire Metsera for USD\u202f7.5\u202fbillion in a definitive deal announced on September\u202f22.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45372","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer","og_description":"Novo Nordisk A\/S (NYSE: NVO) announced today an unsolicited offer of USD\u202f9\u202fbillion for Metsera, Inc. (NASDAQ:\u202fMTSR), a U.S. obesity\u2011drug developer. The bid aims to outpace Pfizer (NYSE: PFE), which had previously agreed to acquire Metsera for USD\u202f7.5\u202fbillion in a definitive deal announced on September\u202f22.","og_url":"https:\/\/flcube.com\/?p=45372","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-31T03:06:37+00:00","article_modified_time":"2025-10-31T03:06:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45372#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45372"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer","datePublished":"2025-10-31T03:06:37+00:00","dateModified":"2025-10-31T03:06:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45372"},"wordCount":289,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45372#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101.webp","keywords":["Biotech","Finance","Metsera","NASDAQ: MTSR","Novo Nordisk","NYSE: NVO","NYSE: PFE","Pfizer"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45372#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45372","url":"https:\/\/flcube.com\/?p=45372","name":"Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45372#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45372#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101.webp","datePublished":"2025-10-31T03:06:37+00:00","dateModified":"2025-10-31T03:06:38+00:00","description":"Novo Nordisk A\/S (NYSE: NVO) announced today an unsolicited offer of USD\u202f9\u202fbillion for Metsera, Inc. (NASDAQ:\u202fMTSR), a U.S. obesity\u2011drug developer. The bid aims to outpace Pfizer (NYSE: PFE), which had previously agreed to acquire Metsera for USD\u202f7.5\u202fbillion in a definitive deal announced on September\u202f22.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45372#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45372"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45372#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101.webp","width":1080,"height":608,"caption":"Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45372#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Launches $9\u202fBillion Unsolicited Bid for Metsera, Triggering Battle with Pfizer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45372","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45372"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45372\/revisions"}],"predecessor-version":[{"id":45374,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45372\/revisions\/45374"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45373"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45372"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45372"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}